Carlyle, GTCR Ink $21.75-Per-Share Buyout Of AMRI
Law360, New York (June 6, 2017, 9:00 PM EDT) -- Life sciences research and development company Albany Molecular Research Inc. will be bought out by The Carlyle Group and GTCR LLC for $21.75 per share in cash, a 40 percent premium, the firms announced Tuesday.
Based on the 42.93 million shares outstanding disclosed in AMRI’s most recent quarterly report, the offer values the company’s stock at about $933 million. The deal marks a 40 percent premium to the 60-day weighted average closing price as of April 5, when media reports concerning a potential buyout started to surface, AMRI said.
AMRI, based in Albany, New York, lauded the transaction as a testament to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!